The cancer treatment technology developer's series C was led by Philips Health Technology Ventures and backed by Debiopharm and Cerner.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Fresenius Medical Care and Access Industries-backed Humacyte will merge with Alpha Healthcare Acquisition Corp to become a public business with a market cap of $1.1bn.

Merck and Novartis joined a host of philanthropic and state-backed entities for a $300m fund that will invest in medical technologies for conditions often ignored by venture capital.

Rogue has achieved a first close for its fourth fund, although it is as-yet unclear whether Oregon State University is again an investor.

The Medtronic-backed medical device maker has pulled in $108m in equity financing just under a year after delisting.

University of Oxford and OSI have both returned for a $95.4m series C round that also included GV and, through the conversion of a note, Eli Lilly.

GV has returned for a $95.4m series C round that also included Eli Lilly through the conversion of a $10m note secured as part of a collaboration agreement last year.

The Legend Holdings-backed digital medical platform has raised fresh capital for a series A round led by Qiming Venture Partners.

Amadeus Capital Partners has bought a stake in the Amgen and Illumina-backed company through a secondary transaction, valuing it at around $2.4bn.